10-Q: Azitra Faces Going Concern Amid Rising Losses

Azitra, Inc. reported increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and new financing efforts.

Summary

• Azitra, Inc. reported a net loss of $5,957,338 for the six months ended June 30, 2025, an increase from $5,564,868 in the prior year period.
• Cash and cash equivalents decreased significantly to $1,045,730 as of June 30, 2025, down from $4,554,719 at December 31, 2024.
• The company used $5,886,798 in cash for operating activities during the first six months of 2025, an increase from $5,121,955 in the same period of 2024.
• Total revenue for the six months ended June 30, 2025, was $0, compared to $7,500 in the prior year, with no further service revenue expected.
• Research and development expenses increased by 2% to $2,651,939 for the six months ended June 30, 2025, driven by clinical trial progression for ATR-12 and ATR-04 programs.
• General and administrative costs rose by 9% to $3,319,651 for the six months ended June 30, 2025, primarily due to increased accounting, legal, and public relations fees.
• The company has an accumulated deficit of $63.5 million and working capital of $0.3 million as of June 30, 2025.
• A material weakness in internal control over financial reporting was identified due to a lack of adequate segregation of accounting functions.
• Stockholders approved a potential further reverse stock split (1:2 to 1:7 ratio) on February 20, 2025, with the Board still evaluating the exact ratio and timing.
• The number of authorized shares was increased from 100,000,000 to 200,000,000 in July 2025.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to significant financial distress, including increased losses, substantial cash burn, and an explicit 'going concern' warning. While clinical programs are progressing and new financing has been secured, the company's liquidity position and reliance on further dilutive capital raises present considerable challenges. The identified material weakness in internal controls further adds to the negative outlook.

Positives

• Initial clinical safety results for the ATR-12 program in Netherton syndrome patients were reported in the first half of 2025.
• The ATR-04 program received IND clearance from the FDA in August 2024 and Fast Track designation in September 2024, with a Phase 1b trial commenced in Q4 2024.
• The company secured an Equity Line of Credit (ELOC) with Alumni Capital LP for up to $20 million, with $18.3 million still available as of August 11, 2025.
• Stockholders approved the sale and issuance of more than 19.99% of outstanding shares under the ELOC on June 23, 2025, facilitating future capital raises.

Negatives

• Net loss increased by 10% for the three months ended June 30, 2025, and by 7% for the six months ended June 30, 2025, compared to prior year periods.
• Cash and cash equivalents significantly declined from $4.55 million at year-end 2024 to $1.05 million by June 30, 2025.
• The company's cash on hand is not sufficient to cover its proposed plan of operations for the next twelve months.
• A material weakness in internal control over financial reporting was identified due to inadequate segregation of accounting functions.
• The company has ceased generating service revenue from related parties and does not expect further revenue at this time.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to significant accumulated deficit, operating losses, and cash used in operations.
• The company will require a significant amount of additional funds to complete product development and fund future losses, with no assurance of securing additional financing on reasonable terms.
• Future equity or convertible debt financings will dilute common stockholders' ownership interests.
• Changes in U.S. and international trade policies, including tariffs, could increase the cost of manufacturing product candidates and supporting materials, or impact import/export of raw materials.
• Dependence on contract research organizations (CROs) and contract manufacturing organizations (CMOs) exposes the company to risks of operational interruptions or supply chain issues.
• Product candidates require FDA or other international regulatory approvals, and denial, delays, or inability to maintain approvals could materially adversely impact the company.
• The company is subject to risks common in the pharmaceutical industry, including new technological innovations by competitors, dependence on key personnel, and protection of proprietary technology.

Future Outlook

Management believes current cash on hand will not be sufficient to cover proposed operations for the next twelve months and plans to continue raising funds through equity and/or debt financing. Research and development expenses are expected to significantly increase due to planned clinical trial activity and continued product candidate development. General and administrative expenses are expected to modestly increase due to personnel, facility costs, and public company compliance.

Management Comments

• "We believe that our cash on-hand as of the date of this report will not be sufficient to cover our proposed plan of operations over the next twelve months."
• "Management plans to continue to raise funds through equity and/or debt financing to fund operating and working capital needs."
• "We expect that our general and administrative expenses will incur a modest increase in the future as a result of personnel costs, and facility operating costs."
• "We expect our research and development expenses to significantly increase in the future due primarily to our planned clinical trial activity and continued development of product candidates."

Industry Context

Azitra operates in the highly capital-intensive and regulated biopharmaceutical industry, specifically focusing on precision dermatology using synthetic biology. The company's strategy to leverage a proprietary microbial library and AI/machine learning for genetically engineered therapies aligns with broader trends in personalized medicine and advanced biologics. However, as an early-stage clinical company, it faces significant financial hurdles common to the sector, including high R&D costs and a prolonged path to commercialization, necessitating continuous capital raises.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• No related party revenue for the three and six months ended June 30, 2025. Total related party revenue was $7,500 for the three and six months ended June 30, 2024.
• Bayer was no longer considered a related party as of July 2024, as their holdings no longer exceeded 5% of total outstanding common stock.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future equity raises, potential negative impact from reverse stock splits, and uncertainty due to the 'going concern' warning.
• **Employees**: Potential impact on job security and morale due to financial instability and the 'going concern' warning, though the company is addressing internal control weaknesses by increasing accounting staff.
• **Customers (Future)**: No direct impact yet as the company is pre-commercialization, but successful product development and commercialization are contingent on securing sufficient funding.
• **Suppliers/Creditors**: Increased risk due to the company's financial condition and 'going concern' warning, potentially impacting payment terms or willingness to extend credit.
• **Regulatory Authorities**: The company continues to engage with the FDA for clinical trial approvals and designations, indicating ongoing compliance efforts despite financial challenges.

Next Steps

• Dose the first patient in the ATR-04 Phase 1/2 clinical trial in the third quarter of 2025.
• Perform lead optimization and IND-enabling studies for the ATR-01 program in 2025 to support an IND filing in 2026.
• Continue to raise funds through equity and/or debt financing to meet operating and working capital needs.
• Increase staffing within the accounting infrastructure to address the material weakness in internal controls related to segregation of accounting functions.
• The Board will continue evaluating the need for a further reverse stock split and, if needed, determine the exact split ratio and timing.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt' about its ability to continue as a going concern. It has a rapidly declining cash balance, increasing net losses, and no current revenue streams. While clinical programs show progress and new financing has been secured, the reliance on continuous, highly dilutive capital raises, coupled with an identified material weakness in internal controls, indicates a high level of operational and financial risk. The significant dilution from recent and planned equity offerings, along with the potential for further reverse stock splits, makes the stock a high-risk investment with a strong likelihood of further value erosion for current shareholders.

Keywords

Biopharmaceutical, Dermatology, Synthetic Biology, Clinical Trials, SEC Filing, Going Concern, ATR-12, ATR-04, ATR-01, Netherton Syndrome, EGFRi Rash, Ichthyosis Vulgaris, Equity Line of Credit, Reverse Stock Split, Warrants, Research and Development